Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. MorphoSys AG
  6. Summary
    MOR   DE0006632003

MORPHOSYS AG

(MOR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
01/17/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
29.51(c) 28.91(c) 29.03(c) 29.34(c) 28.45 Last
206 739 232 088 240 777 199 286 84 331 Volume
-0.51% -2.03% +0.42% +1.07% -3.03% Change
More quotes
Estimated financial data (e)
Sales 2021 175 M 198 M 198 M
Net income 2021 -176 M -199 M -199 M
Net cash position 2021 174 M 197 M 197 M
P/E ratio 2021 -4,13x
Yield 2021 -
Sales 2022 262 M 296 M 296 M
Net income 2022 -201 M -228 M -228 M
Net cash position 2022 258 M 293 M 293 M
P/E ratio 2022 -4,72x
Yield 2022 -
Capitalization 1 002 M 1 136 M 1 135 M
EV / Sales 2021 4,72x
EV / Sales 2022 2,84x
Nbr of Employees 771
Free-Float -
More Financials
Company
MorphoSys AG is one of the world's leading groups of biotechnology. Net sales break down by activity as follows: - development of antibody for therapeutic applications in partnership with pharmaceutical and biotechnology companies (52.2%): for treating rheumatoid arthritis, cancers and infectious diseases; - proprietary development of therapeutic antibodies and peptides (47.8%). At the end of 2019, the MorphoSys... 
Sector
Biotechnology & Medical Research
Calendar
03/16 | 04:00pmEarnings Release
More about the company
Ratings of MorphoSys AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about MORPHOSYS AG
01/17MORPHOSYS : JP Morgan reiterates its Neutral rating
MD
01/14European ADRs Move Higher in Friday Trading
MT
01/14Morgan Stanley Downgrades MorphoSys to Equalweight from Overweight, Adjusts Price Targe..
MT
01/11MORPHOSYS : Notification of managers`transactions according to article 19 MAR - Form 6-K
PU
01/11MORPHOSYS AG : Notification and public disclosure of transactions by persons
EQ
01/10MORPHOSYS : To Present At the 40th Annual J.P. Morgan Healthcare Conference - Form 6-K
PU
01/10European ADRs Move Lower in Monday Trading
MT
01/10MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guida..
AQ
01/10MORPHOSYS : Barclays remains Neutral
MD
01/10MORPHOSYS : Deutsche Bank remains Neutral
MD
01/10MORPHOSYS : To Present At the 40th Annual J.P. Morgan Healthcare Conference
PU
01/10MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference
EQ
01/07European ADRs Move Higher in Friday Trading
MT
01/07MORPHOSYS : Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidan..
PU
01/07MORPHOSYS : JP Morgan remains Neutral
MD
More news
News in other languages on MORPHOSYS AG
01/14Les ADR européens sont en hausse vendredi
01/14Morphosys rutschen ab - Morgan Stanley pessimistischer
01/14BOLSA DE MADRID : Good cop, bad cop
01/14Good cop, bad cop
01/14AVIS D'ANALYSTES DU JOUR : Safran, Novartis, Esker, Zalando, Shop Apotheke, Givaudan, Equi..
More news
Analyst Recommendations on MORPHOSYS AG
More recommendations
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 29,34 €
Average target price 59,68 €
Spread / Average Target 103%
EPS Revisions
Managers and Directors
Jean-Paul Kress CEO & Chairman-Management Board
Sung H. Lee Chief Financial Officer
Marc Cluzel Chairman-Supervisory Board
Malte Peters Chief Research & Development Officer
Armin Weidmann Head-Compliance & Quality Assurance
Sector and Competitors
1st jan.Capi. (M$)
MORPHOSYS AG-12.02%1 136
MODERNA, INC.-34.04%67 921
LONZA GROUP AG-13.71%53 315
IQVIA HOLDINGS INC.-13.38%46 690
SEAGEN INC.-13.93%24 331
ICON PUBLIC LIMITED COMPANY-17.37%20 831